A drug from Celgene and Acceleron Pharma has met the main goals of a late-stage test as a treatment for a rare blood disorder, the second set of positive results that the partners have released for the drug in as many weeks.
The latest announcement covered use of the drug, luspatercept, as a treatment for beta-thalassemia, which is an inherited disease that causes patients to have low levels of oxygen-carrying red blood cells. The disease is currently treated with monthly transfusions to prevent anemia, a shortage of red blood cells. Patients also need iron chelation therapy to flush out the… Read more »
UNDERWRITERS AND PARTNERS